Why the study?
Does early antiplatelet therapy reduce major adverse events in patients with acute coronary syndromes who may require coronary artery bypass grafting?
Does early antiplatelet therapy reduce major adverse events in patients with acute coronary syndromes who may require coronary artery bypass grafting?
This review highlights that the benefits of early antiplatelet therapy generally outweigh the bleeding risks in ACS patients who may require CABG.
Supports early antiplatelet consideration in ACS patients proceeding to CABG; leaves open need for randomized confirmation before practice change.
Studies have demonstrated that antagonists of platelet activity, including aspirin and clopidogrel, reduce the risk of major adverse events in patients with acute coronary syndromes. Although antiplatelet agents also convey an increased risk of bleeding, particularly in patients proceeding to coronary artery bypass graft surgery, in most cases, the benefits of early initiation of antiplatelet therapy outweigh the risks. The purpose of this review is to distinguish perceived and actual risk versus the benefit associated with early antiplatelet therapy to help clinicians make informed decisions on using these agents in an acute setting where patients may require coronary artery bypass grafting.
No takes yet. Share an insight, caveat, or question.
Gregory D. Trachiotis (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: